Technical Analysis for ALT - Altimmune, Inc.

Grade Last Price % Change Price Change
D 12.57 -4.63% -0.61
ALT closed down 8.28 percent on Thursday, March 4, 2021, on 1.27 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Mar 25
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical ALT trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion -5.39%
Below Lower BB Weakness -5.39%
Down 3 Days in a Row Weakness -5.39%
Lower Bollinger Band Touch Weakness -5.39%
Oversold Stochastic Weakness -5.39%
50 DMA Resistance Bearish -13.22%
Fell Below 200 DMA Bearish -13.22%
MACD Bearish Centerline Cross Bearish -13.22%
Wide Bands Range Expansion -13.22%
Oversold Stochastic Weakness -13.22%
Older End-of-Day Signals for ALT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Previous Day's Low about 3 hours ago
Down 10% about 3 hours ago
60 Minute Opening Range Breakdown about 3 hours ago
Down 5% about 4 hours ago
Fell Below Lower Bollinger Band about 4 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Altimmune, Inc. Description

Altimmune,Inc., formerly Pharmathene, Inc., is a biodefense company. The Company is focused on the development of medical counter measures against biological and chemical threats. The Company is involved in the development of two next generation anthrax vaccines. The Company's anthrax vaccines use recombinant protective antigen (rPA) manufacturing processes. The Company's product portfolio includes recombinant butyrylcholinesterase (rBChE) bioscavenger, which is used in prevention and treatment of nerve agent poisoning. The Company has developed a recombinant form of human butyrylcholinesterase for pre- and post-exposure therapy to patients with nerve agent attacks. Its rBChE bioscavenger acts with mechanism, which includes reversal of the acute toxicity associated with organophosphate poisoning agents used in chemical warfare (cholinergic crisis). Its development program also includes Valortim for monoclonal human antibody treatment.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Phosphate Manufacturing Process Vaccine Nerve Reversal Manufacturing Processes Choline Biodefense Biological Warfare Anthrax Chemical Warfare Cholinesterase Anthrax Vaccines Athene

Is ALT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 35.1
52 Week Low 2.5
Average Volume 1,724,677
200-Day Moving Average 14.85
50-Day Moving Average 15.90
20-Day Moving Average 19.27
10-Day Moving Average 17.41
Average True Range 2.00
ADX 33.31
+DI 16.25
-DI 36.00
Chandelier Exit (Long, 3 ATRs ) 18.60
Chandelier Exit (Short, 3 ATRs ) 18.23
Upper Bollinger Band 25.38
Lower Bollinger Band 13.16
Percent B (%b) 0.0
BandWidth 63.43
MACD Line -0.39
MACD Signal Line 0.71
MACD Histogram -1.1018
Fundamentals Value
Market Cap 435.88 Million
Num Shares 33.1 Million
EPS -4.16
Price-to-Earnings (P/E) Ratio -3.17
Price-to-Sales 40.41
Price-to-Book 2.12
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.29
Resistance 3 (R3) 16.31 15.30 15.77
Resistance 2 (R2) 15.30 14.51 15.29 15.59
Resistance 1 (R1) 14.24 14.02 13.74 14.22 15.42
Pivot Point 13.23 13.23 12.98 13.22 13.23
Support 1 (S1) 12.17 12.44 11.67 12.15 10.94
Support 2 (S2) 11.16 11.95 11.15 10.77
Support 3 (S3) 10.10 11.16 10.59
Support 4 (S4) 10.08